Genome Medicine’s editors recently published an article outlining what they felt were the most exciting breakthroughs in research in the past 2 years and what (in their opinion) the future of genomic medicine might hold. Below is a brief summary of their recommended steps for improvement over the next two years.
- improved analytical power to keep pace with falling costs and exponential increase in DNA sequencing capabilities of whole-genome sequencing
- a plan for dealing with the “public’s” perception of genomic research and their need for “control” over their own genetic samples
- a plan for closing the gap between discovery and clinical validity of personalized medicine
- the need to develop a multidisciplinary translation research agenda
- to be able to characterize all forms of genetic variation in an individual patient’s genome including single or simple nucleotide variation (SNV) and copy number variation (CNV)
- more complete tools for the physician including information on individual genetic make-up of the patient which can be used to guide the selection of drugs or treatment processes
- increased sensitivity of proteomics-based analytical techniques that will enable identification of disease-specific biomarkers and enhanced quantitative measurement of specific proteins in clinical samples
The editorial represents the opinions of editors in the USA, Canada, Germany and France and can therefore be assumed to be universally relevant.
For more information see Genome Medicine: past, present and future